From metabolic pathways to biomarkers: where are we now with metabolomics in Alzheimer’s disease?

ISSN： 1479-6708

Source： Future Neurology, Vol.8, Iss.5, 2013-09, pp. : 491-494

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Biomarkers to advance drug development for Alzheimer’s disease

By Schulman Howard

Future Neurology, Vol. 1, Iss. 4, 2006-07 ,pp. : 409-415

Future Medicine

Access to resources Recommend Favorite

Diagnosis of Alzheimer's Disease from EEG Signals: Where Are We Standing?

Current Alzheimer Research, Vol. 7, Iss. 6, 2010-09 ,pp. : 487-505

Bentham Science Publishers

Access to resources Recommend Favorite

Impaired Renal Function and Biomarkers of Vascular Disease in Alzheimer’s Disease

Current Alzheimer Research, Vol. 11, Iss. 3, 2014-03 ,pp. : 253-258

Bentham Science Publishers

Access to resources Recommend Favorite

F₂-Isoprostanes as Biomarkers of Late-onset Alzheimer’s Disease

By Montine Thomas Quinn Joseph Kaye Jeffrey Morrow Jason

Journal of Molecular Neuroscience, Vol. 33, Iss. 1, 2007-09 ,pp. : 114-119

Humana Press, Inc

Access to resources Recommend Favorite

Novel CSF biomarkers for Alzheimer’s disease and mild cognitive impairment

By Hu William Chen-Plotkin Alice Arnold Steven Grossman Murray Clark Christopher Shaw Leslie Pickering Eve Kuhn Max Chen Yu McCluskey Leo Elman Lauren Karlawish Jason Hurtig Howard Siderowf Andrew Lee Virginia Soares Holly Trojanowski John

Acta Neuropathologica, Vol. 119, Iss. 6, 2010-06 ,pp. : 669-678

Springer Publishing Company

Access to resources Recommend Favorite